Universal Beteiligungs und Servicegesellschaft mbH Takes $125,000 Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 16,704 shares of the biotechnology company’s stock, valued at approximately $125,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Eversept Partners LP boosted its position in BioCryst Pharmaceuticals by 269.9% during the fourth quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company’s stock worth $14,892,000 after purchasing an additional 1,444,907 shares in the last quarter. Balyasny Asset Management L.P. acquired a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter valued at $3,983,000. Norges Bank acquired a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter valued at $3,947,000. Woodline Partners LP purchased a new position in BioCryst Pharmaceuticals in the fourth quarter valued at $3,385,000. Finally, Caligan Partners LP boosted its holdings in BioCryst Pharmaceuticals by 16.0% in the fourth quarter. Caligan Partners LP now owns 2,995,932 shares of the biotechnology company’s stock valued at $22,529,000 after purchasing an additional 412,347 shares during the period. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Trading Down 4.2%

Shares of BCRX opened at $8.36 on Wednesday. The firm has a market capitalization of $1.75 billion, a P/E ratio of -46.44, a price-to-earnings-growth ratio of 1.43 and a beta of 1.10. The stock’s fifty day simple moving average is $9.46 and its 200 day simple moving average is $8.74. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.01 and a twelve month high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.03 by $0.12. The company had revenue of $163.35 million during the quarter, compared to analysts’ expectations of $149.59 million. The company’s revenue for the quarter was up 49.5% compared to the same quarter last year. During the same period last year, the business earned ($0.06) earnings per share. Sell-side analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on BCRX shares. Barclays lifted their price target on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $17.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Monday. Bank of America boosted their target price on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday, July 1st. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. Finally, Wedbush increased their target price on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an “outperform” rating in a report on Monday, June 30th. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $16.70.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.